Filing Details
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on October 29, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:VNDA
Vanda Pharmaceuticals Inc. (VNDA) Files Quarterly Report for Q0
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on October 29, 2026.
At publication ·
What changed
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Vanda Pharmaceuticals filed its Q0 2026 quarterly report (Form 10-Q) with the SEC on October 29, 2026.
- The company's stock trades at $4.05 per share with a market capitalization of $390.0 million.
- The 10-Q filing includes unaudited financial statements and management commentary on business performance and emerging trends.
Market Context
Vanda Pharmaceuticals Inc.'s stock currently trades at $4.05 with a market capitalization of $390.0M.
The 10-Q provides Vanda Pharmaceuticals Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Vanda Pharmaceuticals Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View VNDA Stock Page
Frequently Asked Questions
Where can I read VNDA's SEC filings?
Browse all filings on our VNDA SEC filings page.
What types of SEC filings does Vanda Pharmaceuticals Inc. file?
Public companies like Vanda Pharmaceuticals Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.